The ELAVL2 Knockout NCI-H1975 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma cell line, featuring targeted disruption of the ELAVL2 gene. This gene-edited population provides a loss-of-function model to investigate the role of the ELAVL2 RNA-binding protein in post-transcriptional gene regulation within a non-small cell lung cancer background. As a polyclonal knockout pool, the cells retain heterogeneous editing outcomes, enabling robust functional studies without clonal selection bias.
The parental NCI-H1975 cell line is derived from a female non-smoker with lung adenocarcinoma and harbors endogenous EGFR L858R and T790M mutations, making it a well-characterized model of non-small cell lung adenocarcinoma with activated EGFR signaling. These cells exhibit epithelial morphology and are widely used for studying oncogenic kinase signaling and drug resistance mechanisms. The combination of the EGFR-mutant background with ELAVL2 knockout allows dissection of RNA-mediated regulatory layers superimposed on the driver oncogene.
ELAVL2 encodes an RNA-binding protein that selectively binds AU-rich elements (AREs) in the 3?? untranslated regions of target mRNAs, conferring enhanced transcript stability. Known downstream targets include GAP43, c-fos, and neurofilament mRNAs, along with other ARE-containing transcripts encoding oncogenic and neural factors. ELAVL2 interacts with hnRNP proteins, microRNA machinery components, and ARE-binding protein complexes, integrating post-transcriptional control with signaling cascades. In the context of EGFR-driven lung adenocarcinoma, ELAVL2 may modulate the stability of mRNAs encoding components of the MAPK/ERK and PI3K/AKT pathways, thereby influencing proliferation and survival signals downstream of mutant EGFR.
Disruption of ELAVL2 in NCI-H1975 cells is expected to alter the stability of a subset of ARE-containing transcripts, potentially affecting oncogene expression, cell cycle progression, and apoptotic thresholds. Given the reliance of NCI-H1975 cells on EGFR signaling, ELAVL2 knockout may reveal RNA-dependent mechanisms that modulate sensitivity to EGFR tyrosine kinase inhibitors. This model is particularly relevant for investigating how post-transcriptional regulation contributes to tumor cell plasticity and the acquisition of neural-like phenotypes observed in lung adenocarcinoma.
Researchers can use this polyclonal knockout population for functional studies of RNA-binding proteins in lung cancer, post-transcriptional regulation of oncogenes, and drug target validation. Typical assays include western blotting, RT-qPCR, RNA-seq-based mRNA stability analysis, proliferation and migration assays, and drug sensitivity testing with EGFR inhibitors. For further information or to discuss custom gene-edited cell solutions, please contact Ascent Research.
